Cargando…

Development and validation of a hypoxia-associated signature for lung adenocarcinoma

Hypoxia is common in non-small cell lung cancer (NSCLC) and an attractive therapeutic target. As hypoxia-targeting treatments are effective in patients with the most hypoxic tumours, we aimed to develop a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lane, Brian, Khan, Mairah T., Choudhury, Ananya, Salem, Ahmed, West, Catharine M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789914/ https://www.ncbi.nlm.nih.gov/pubmed/35079065 http://dx.doi.org/10.1038/s41598-022-05385-7

Ejemplares similares

A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer
por: Khan, Mairah T., et al.
Publicado: (2021)

Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma
por: Forker, Laura J., et al.
Publicado: (2023)

Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts
por: Yang, Lingjian, et al.
Publicado: (2017)

Correction: Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts
por: Yang, Lingjian, et al.
Publicado: (2019)

Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
por: Yang, Lingjian, et al.
Publicado: (2018)

The effect of hypoxia on PD-L1 expression in bladder cancer
por: Smith, Vicky, et al.
Publicado: (2021)

Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma
por: Tian, Xiong, et al.
Publicado: (2022)

Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma
por: Li, Yong, et al.
Publicado: (2022)

Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients
por: Sun, Jing, et al.
Publicado: (2020)

Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer
por: Smith, Vicky, et al.
Publicado: (2023)

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
por: Sun, Sijin, et al.
Publicado: (2020)

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma
por: Huang, Hua, et al.
Publicado: (2022)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma
por: Park, Yun-Yong, et al.
Publicado: (2012)

Development and validation of an immune‐related gene signature for prognosis in Lung adenocarcinoma
por: Guo, Zehuai, et al.
Publicado: (2023)

Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer
por: Smith, Vicky, et al.
Publicado: (2022)

Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma
por: Zhang, Yingqing, et al.
Publicado: (2020)

Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma
por: Zhang, Anran, et al.
Publicado: (2021)

Development and validation of a combined ferroptosis and immune prognostic signature for lung adenocarcinoma
por: Li, Han, et al.
Publicado: (2022)

Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
por: Wang, Ning, et al.
Publicado: (2023)

Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients
por: Shi, Run, et al.
Publicado: (2021)

Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma
por: Wang, Jiao, et al.
Publicado: (2020)

Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2022)

Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma
por: Dai, Zili, et al.
Publicado: (2021)

Development and validation of an immune‐related prognosis signature associated with hypoxia and ferroptosis in hepatocellular carcinoma
por: Yang, Chun‐Bo, et al.
Publicado: (2022)

Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients
por: Shao, Jun, et al.
Publicado: (2021)

Development and validation of a hypoxia-related prognostic signature for breast cancer
por: Wang, Jianxin, et al.
Publicado: (2020)

Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma
por: Wu, Pancheng, et al.
Publicado: (2020)

Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2021)

Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma
por: Tian, Qi, et al.
Publicado: (2021)

Development and validation of a TRP-related gene signature for overall survival prediction in lung adenocarcinoma
por: He, Min, et al.
Publicado: (2022)

Corrigendum: Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2023)

Development of a gene signature associated with iron metabolism in lung adenocarcinoma
por: Qin, Junqi, et al.
Publicado: (2021)

Construction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma
por: Chen, Qirui, et al.
Publicado: (2023)

Development and Validation of a Hypoxia-Associated Prognostic Signature Related to Osteosarcoma Metastasis and Immune Infiltration
por: Fu, Yucheng, et al.
Publicado: (2021)

Construction and validation of a 15-gene ferroptosis signature in lung adenocarcinoma
por: Tu, Guangxu, et al.
Publicado: (2021)

Identification and validation of GABA‐driven subtypes and prognosis signature of lung adenocarcinoma
por: Li, Lifeng, et al.
Publicado: (2023)

Development and Validation of a 6-Gene Hypoxia-Related Prognostic Signature For Cholangiocarcinoma
por: Sun, Qi, et al.
Publicado: (2022)

Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer
por: Zhong, Jianxin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uhe1h2hi8she88iv7s68gl8ab8